Get the Stockscreener App
32.60
1.78%
-0.59
After Hours:
32.25
-0.35
-1.07%
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Spinal Muscular Atrophy Pipeline 2024: Key Companies, MOA, ROA, - openPR
ARK Investment Management LLC Sells 359,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.00 Consensus Target Price from Analysts - MarketBeat
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs - MarketBeat
Intellia: Balancing in vivo risk with validated targets - BioCentury
Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Equities Analysts Set Expectations for IONS Q1 Earnings - MarketBeat
Leerink upgrades Ionis to outperform, cites Angelman drug - MSN
Ionis to present at upcoming investor conferences - Post Register
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Pharmaceuticals EVP Patrick O'Neil sells $39,046 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Officer Sells Shares - TradingView
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $45.00 by Analysts at BMO Capital Markets - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Earnings Results - MarketBeat
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches - MSN
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James - Yahoo Finance
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - BioSpace
Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued - Morningstar
Ionis posts Q4 beat as revenue base widens - MSN
Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel - MSN
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Ionis presents new data on HAE drug donidalorsen By Investing.com - Investing.com Nigeria
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript - Insider Monkey
Ionis stock target cut to $60 by Raymond James - Investing.com India
Ionis presents new data on HAE drug donidalorsen - Investing.com
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Can This New HAE Treatment Transform Patient Care? Key Clinical Data Revealed - StockTitan
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Ionis Pharmaceuticals: Q4 Earnings Snapshot - The Advocate
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - MSN
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Pharmaceuticals: Positive Sentiment in Earnings Call - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Quotes, Forecast and News Summary - Benzinga
Stifel cuts Ionis Pharmaceuticals target to $38, maintains Hold - Investing.com India
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval (IONS) - Seeking Alpha
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - AOL
Ionis Pharma Beats Expectations for Q4 - MSN
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts - Investing.com
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ionis stock gains on Q4 beat (IONS:NASDAQ) - Seeking Alpha
Ionis reports fourth quarter and full year 2024 financial results - BioSpace
Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set - Marketscreener.com
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus - Investing.com Nigeria
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):